The role of chemokines in hypertension

Advances in Clinical and Experimental Medicine

Volumn 23, Issue 3, 2014, Pages 319-325

  Martynowicz, Helena ^a   Janus, Agnieszka ^a   Nowacki, Dorian ^a   Mazur, Grzegorz ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Chemokines; Endothelium; Hypertension

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHEMOKINE; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR3; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; FRACTALKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LOSARTAN; MONOCYTE CHEMOTACTIC PROTEIN 1; N [2 [[1 [4 (1,3 BENZODIOXOL 5 YL) 4 HYDROXYCYCLOHEXYL] 4 ETHOXY 3 PYRROLIDINYL]AMINO] 2 OXOETHYL] 3 (TRIFLUOROMETHYL)BENZAMIDE; NITRIC OXIDE; OLMESARTAN; RANTES; TELMISARTAN; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHEMOKINE RECEPTOR CXCR2; ENDOTHELIN 1; GRO ALPHA PROTEIN; ONCOPROTEIN; REPARIXIN; UNCLASSIFIED DRUG;

BLOOD VESSEL WALL; CELL MIGRATION; CELL PROLIFERATION; DIASTOLIC DYSFUNCTION; ENDOTHELIAL DYSFUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; INFLAMMATION; KIDNEY FIBROSIS; MACROPHAGE; MONOCYTE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN FUNCTION; REVIEW; SMOOTH MUSCLE FIBER; ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR INFLAMMATION; MACROPHAGE MIGRATION; MOLECULAR WEIGHT; POLAND; RISK FACTOR; VASCULAR SMOOTH MUSCLE CELL;

ANTI-INFLAMMATORY AGENTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHEMOKINES; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; SIGNAL TRANSDUCTION;

EID: 84905702978     PISSN: 18995276     EISSN: None     Source Type: Journal    
DOI: 10.17219/acem/37123     Document Type: Review

References (52)

1. Zdrojewski T, Bandosz P, Gaciong Z, Wyrzykowski B: Rozpowszechnienie czynników ryzyka chorób układu sercowo-naczyniowego w Polsce w 2011 r. Zakres wieku 18-79 lat. NATPOL 2011. XV Miȩdzynarodowy Kongres PTK. Wrocław 6-8.10.2011
2. Rodríguez-Iturbe B, Vaziri ND, Herrera-Acosta J, Johnson RJ: Oxidative stress, renal infiltration of immune cells andsalt-sensitive hypertension: all for one and one for all. Am J Physiol 2004, 286, 606-616.
3. Johnson RJ, Alpers CE, Yoshimura A, Lombardi D, Pritzl P, Floege J, Schwartz SM: Renal injury from angiotensin II-mediated hypertension. Hypertension 1992, 19, 464-474.
4. Haller H, Behrend M, Park JK, Schaberg T, Luft FC, Distler A: Monocyte infiltration and c-fms expression in hearts of spontaneously hypertensive rats. Hypertension 1995, 25, 132-138.
5. Aukrust P, Berge, RK, Ueland T, Aaser E, Damås JK, Wikeby L, Brunsvig A, Müller F, Forfang K, Frøland SS, Gullestad L: Interaction between chemokines and oxidative stress possible pathogenic role in acute coronary syndromes. J Am Coll Cardiol 2001, 37, 485-491.
6. Yao HL, Gao FH, Li ZZ, Wu HX, Xu MD, Zhang Z, Dai QY: Monocyte chemoattractant protein-1 mediates angiotensin II-induced vascular smooth muscle cell proliferation via SAPK/JNK and ERK1/2. Mol Cell Biochem 2012, 366, 355-362.
7. Mettimano M, Specchia ML, Ianni A, Arzani D, Ricciardi G, Savi L, Romano-Spica V: CCR5 and CCR2 gene polymorphisms in hypertensive patients. Br J Biomed Sci 2003, 60, 19-21. (Pubitemid 36384742)
8. Arenzana-Seisdedos F, Parmentier M: Genetics of resistance to HIV infection: Role of co-receptors and co-receptor ligands. Semin Immunol 2006, 18, 387-403. (Pubitemid 44511884)
9. Mettimano M, Specchia ML, La Torre G, Bruno A, Ricciardi G, Savi L, Romano-Spica V: Blood pressure regulation by CCR genes. Clin Exp Hypertens 2006, 28, 611-618. (Pubitemid 44596148)
10. Zhang M, Ardlie K, Wacholder S, Welch R, Chanock S, O'Brien TR: Genetic variations in CC chemokine receptors and hypertension. Am J Hypertens 2006, 19, 67-72. (Pubitemid 43217036)
11. Gouraud SS, Waki H, Bhuiyan ME, Takagishi M, Cui H, Kohsaka A, Paton JF, Maeda M: Down-regulation of chemokine Ccl5 gene expression in the NTS of SHR may be pro-hypertensive. J Hypertens 2011, 29, 732-740.
12. Koyanagi M, Egashira K, Kitamoto S, Ni W, Shimokawa H, Takeya M, Yoshimura T, Takeshita A: Role of monocyte chemoattractant protein-1 in cardiovascular remodeling induced by chronic blockade of nitric oxide synthesis. Circulation 2000, 102, 2243-2248.
13. Rodriguez-Iturbe B, Ferrebuz A, Vanegas V, Quiroz Y, Mezzano S, Vaziri ND: Early and sustained inhibition of nuclear factor-kappa B prevents hypertension in spontaneously hypertensive rats. J Pharmacol Exp Ther 2005, 315, 51-57. (Pubitemid 41380497)
14. Wu L, Iwai M, Nakagami H: Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammationinduced vascular injury. Circulation 2001, 104, 2716-2721. (Pubitemid 33108140)
15. Dai Q, Xu M, Yao M, Sun B: Angiotensin AT1 receptor antagonists exert anti-inflammatory effects in spontaneously hypertensive rats. Br J Pharmacol 2007, 152, 1042-1048. (Pubitemid 350166045)
16. Nishio M, Sakata Y, Mano T, Yoshida J, Ohtani T, Takeda Y, Miwa T, Masuyama T, Yamamoto K, Hori M: Therapeutic effects of angiotensin II type 1 receptor blocker at an advanced stage of hypertensive diastolic heart failure. J Hypertens 2007, 25, 455-461. (Pubitemid 46071945)
17. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, Kang MH, Ahn TH, Choi IS, Shin EK: Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004, 14, 110, 3687-3692. (Pubitemid 39665258)
18. Pasceri V, Chang J, Willerson JT, Yeh ET: Modulation of C-reactive protein-mediated monocytechemoattractant protein-1 induction in humanendothelial cells by anti-atherosclerosis drugs. Circulation 2001, 103, 2531-2534. (Pubitemid 32521959)
19. Matsui T, Yamagishi S, Ueda S, Nakamura K, Imaizumi T, Takeuchi M, Inoue H: Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferatoractivated receptor-gamma activation. J Int Med Res 2007, 35, 482-489. (Pubitemid 47261110)
20. Marketou ME, Kontaraki JE, Tsakountakis NA, Zacharis EA, Kochiadakis GE, Arfanakis DA, Parthenakis F, Chlouverakis G, Vardas PE: Differential effect of telmisartan and amlodipine on monocyte chemoattractant protein-1 and peroxisome proliferator-activated receptor-gamma gene expression in peripheral monocytes in patients with essential hypertension. Am J Cardiol 2011, 107, 59-63.
21. Syrbe U, Moebes A, Scholze J, Swidsinski A, Dörffel Y: Effects of the angiotensin II type 1 receptor antagonist telmisartan on monocyte adhesion and activation in patients with essential hypertension. Hypertens Res 2007, 30, 521-528. (Pubitemid 47083122)
22. Lin L, Phillips WE, Manning RD: Intrarenal Angiotensin ii is associated with inflammation, renal damage and dysfunction in dahl salt-sensitive hypertension. J Am Soc Hypertens 2009, 3, 306-314.
23. Ji Xu J, Lin SC, Chen J, Miao Y, Taffet GE, Entman ML, Wang Y: CCR2 mediates the uptake of bone marrowderived fibroblast precursors in angiotensin II-inducd cardiac fibrosis. Am J Physiol Heart Circ Physiol 2011, 301, 538-547.
24. Keeley EC, Mehrad B, Janardhanan R, Salerno M, Hunter JR, Burdick MM, Field JJ, Stricter RM, Kramer CM: Elevated circulating fibrocyte levels in patients with hypertensive heart disease. J Hypertens 2012, 30, 1856-1861.
25. Giunti S, Barutta F, Perin PC, Gruden G: Targeting the MCP-1/CCR2 System in diabetic kidney disease. Curr Vasc Pharmacol 2010, 8, 849-860.
26. Urushihara M, Ohashi N, Miyata K, Satou R, Acres OW, Kobori H: Addition of angiotensin II type 1 receptor blocker to CCR2 antagonist markedly attenuates crescentic glomerulonephritis. Hypertension 2011, 57, 586-593.
27. Zhu XY, Chade AR, Krier JD, Daghini E, Lavi R, Guglielmotti A, Lerman A, Lerman LO: The chemokine monocyte chemoattractant protein-1 contributes to renal dysfunction in swine renovascular hypertension. J Hypertens 2009, 27, 2063-2073.
28. Elmarakby AA, Quigley JE, Olearczyk JJ, Sridhar A, Cook AK, Inscho EW, Pollock DM, Imig JD: Chemokine receptor 2b inhibition provides renal protection in angiotensin II - salt hypertension. Hypertension 2007, 50, 1069-1076. (Pubitemid 350172928)
29. Chan CT, Moore JP, Budzyn K, Guida E, Diep H, Vinh A, Jones ES, Widdop RE, Armitage JA, Sakkal S, Ricardo SD, Sobey CG, Drummond GR: Reversal of vascular macrophage accumulation and hypertension by a CCR2 antagonist in deoxycorticosterone/salt-treated mice. Hypertension 2012, 60, 1207-1212.
30. Mukai Y, Sato S: Polyphenol-containing azuki bean (Vigna angularis) seed coats attenuate vascular oxidative stress and inflammation in spontaneously hypertensive rats. J Nutr Biochem 2011, 22, 16-21.
31. Kim HY, Kang YJ, Song IH, Choi HC, Kim HS: Upregulation of interleukin-8/CXCL8 in vascular smooth muscle cells from spontaneously hypertensive rats. Hypertens Res 2008, 31, 515-523. (Pubitemid 351597506)
32. Li A, Dubey S, Varney ML, Dave BJ, Singh RK: IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003, 170, 3369-3376. (Pubitemid 36302216)
33. Boekholdt S, Peters R, Hack CE, Day NE, Luben R, Bingham SA, Wareham NJ, Reitsma PH, Khaw KT: IL-8 plasma concentrations and the risk of future coronary arterydisease in apparently healthy men and women. Arterioscler Thromb 2004, Vasc Biol 24, 1503-1508.
34. Kim HY, Choi JH, Kang YJ, Park SY, Choi HC, Kim HS: Reparixin, an inhibitor of CXCR1 and CXCR2 receptor activation, attenuates blood pressure and hypertension-related mediators expression in spontaneously hypertensive rats. Biol Pharm Bull 2011, 34, 120-127.
35. Preston IR, Hill NS, Warburton RR, Fanburg BL: Role of 12-lipoxygenase in hypoxia-induced rat pulmonary artery smooth muscle cell proliferation. Am J Lung Cell Mol Physiol 2006, 290, 367-374.
36. Antonelli A, Fallahi P, Ferrari SM, Ghiadoni L, Virdis A, Mancusi C, Centanni M, Taddei S, Ferrannini E: High serum levels of CXC (CXCL10) and CC (CCL2) chemokines in untreated essential hypertension. Int J Immunopathol Pharmacol 2012, 25, 387-395.
37. Talavera D, Castillo AM, Dominguez MC, Gutierrez AE, Meza I: IL8 release, tight junction and cytoskeleton dynamic reorganization conducive to permeability increase are induced by dengue virus infection of microvascular endothelial monolayers. J Gen Virol 2004, 85, 1801-1813. (Pubitemid 39023258)
38. Tsai MK, Jan RL, Lin CH, Kuo CH, Yang SN, Chen HN, Huang MY, Hung CH: Suppressive effects of imidapril on Th1- and Th2-related chemokines in monocytes. J Investig Med 2011, 59, 1141-1146.
39. White GE, Greaves DR: Fractalkine: a survivor's guide: chemokines as antiapoptotic mediators. Arterioscler Thromb Vasc Biol 2012, 32, 589-594.
40. Fong AM, Robinson LA, Steeber DA, Tedder TF, Yoshie O, Imai T, Patel DD: Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 1998, 188, 1413-1419. (Pubitemid 28489578)
41. Wong BW, Wong D, McManus BM: Characterization of Fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. Cardiovasc Pathol 2002, 11, 332-338. (Pubitemid 35380022)
42. Koziolek M J, Müller GA, Zapf A, Patschan D, Schmid H, Cohen CD, Koschnick S, Vasko R, Bramlage C, Strutz F: Role of CX3C-chemokine CX3C-L/fractalkine expression in a model of slowly progressive renal failure. Nephrol Dial Transplant 2010, 25, 684-698.
43. Shimizu K, Furuichi K, Sakai N, Kitagawa K, Matsushima K, Mukaida N, Kaneko S, Wada T: Fractalkine and its receptor, CX3CR1, promote hypertensive interstitial fibrosis in the kidney. Hypertens Res 2011, 34, 747-752.
44. De la Sierra A, Larrousse M: Endothelial dysfunction is associated with increased levels of biomarkers in essential hypertension. J Hum Hypertens 2010, 24, 373-379.
45. Böger RH, Bode-Böger SM, Tsao PS, Lin PS, Chan JR, Cooke JP: An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol 2000, 36, 2287-2295.
46. Rius C, Piqueras L, González-Navarro H, Albertos F, Company C, López-Ginés C, Ludwig A, Blanes JI, Morcillo EJ, Sanz MJ: Arterial and venous endothelia display differential functional fractalkine (CX3CL1) expression by angiotensin-II. Arterioscler Thromb Vasc Biol 2013, 33, 96-104.
47. Schäfer A, Schulz C, Fraccarollo D, Tas P, Leutke M, Eigenthaler M, Seidl S, Heider P, Ertl G, Massberg S, Bauersachs J: The CX3C chemokine fractalkine induces vascular dysfunction by generation of superoxide anions. Arterioscler Thromb Vasc Biol 2007, 27, 55-62. (Pubitemid 46360381)
48. Cheng M, Li Y, Wu J, Nie Y, Li L, Liu X, Charoude HN, Chen H: IL-8 induces imbalances between nitric oxide and endothelin-1, and also between plasminogen activator inhibitor-1 and tissue-type plasminogen activator in cultured endothelial cells. Cytokine 2008, 41, 9-15.
49. DangLi R, HeKong W, JiQin L, MingHua Z, WenCheng Z: ROS-induced ZNF580 expression: a key role for H202/NF-κB signaling pathway in vascular endothelial inflammation. Mol Cell Biochem 2012, 359, 183-191.
50. Yamagishi S, Inagaki Y, Nakamura K, Imaizumi T: Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties. J Cardiovasc Pharmacol 2004, 43, 724-730. (Pubitemid 38534074)
51. Boisvert WA: The participation of chemokines in atherosclerosis. Discov Med 2004, 4, 288-292.
52. Schober A: Chemokines in Vascular Dysfunction and Remodeling, Arterioscler Thromb Vasc Biol 2008, 28, 1950-1959.